Therapeutics for infections caused by Gram-negative pathogens

The scope is restricted to direct-acting therapeutic molecules with confirmed activity against a specific bacterial target. Strategies requiring potentiator molecules (including but not limited to BLIs, efflux inhibitors, membrane permeators) are not within scope. Molecules with properties that can deliver an oral or IV/oral option are preferred. In all cases, activity against both susceptible and multidrug-resistant organisms on the priority bacterial threat lists is essential. We particularly encourage products that target WHO critical priority pathogens and that would be suitable for use in low-resource settings. 

View updated Target Product Profiles and minimal entry criteria here. 

Diagnostics for typhoid fever for low-resource settings

Seeking diagnostics to support the portfolio to diagnose acute infection with Salmonella enterica serovar Typhi or Paratyphi, the causative pathogens in typhoid fever. There are two categories of diagnostics: 

1. Rapid Diagnostic Test: The primary health care level is the preferred use setting, with ease-of-use, high performance and affordability prioritized. View Preferred Product Characteristics and minimal entry criteria here. 
2. Lab Test: Diagnostics for level 2 and above health care settings, with the ability to detect and distinguish between S.enterica Typhi and Paratyphi and the ability to provide antibiotic susceptibility or resistance results. View Preferred Product Characteristics and minimal entry criteria here.